1. Crossnohere, NL, Fischer, R, Lloyd, A, Prosser, LA, Bridges, JF. Assessing the appropriateness of the EQ-5D for Duchenne muscular dystrophy: a patient-centered study. Med Decis Making. 2021;41(2):209–21. https://doi.org/10.1177/0272989x20978390
Google Scholar2. Prinsen, CA, Mokkink, LB, Bouter, LM, et al. COSMIN guideline for systematic reviews of patient-reported outcome measures. Qual Life Res. 2018;27(5):1147–57. https://doi.org/10.1007/s11136-018-1798-3
Google Scholar3. Facey, K, Whittal, A, Drummond, M, Upadhyaya, S, Junghans, T, Nicod, E. IMPACT HTA WP10 HTA appraisal framework suitable for rare disease treatments. Available from: https://www.impact-hta.eu/work-package-10/. Accessed June 23, 2021.
Google Scholar4. Duchenne UK . Project Hercules. Available from: https://hercules.duchenneuk.org/. Accessed June 23, 2021.
Google Scholar5. Powell, PA, Carlton, J, Woods, HB, Mazzone, P. Measuring quality of life in Duchenne muscular dystrophy: a systematic review of the content and structural validity of commonly used instruments. Health Qual Life Outcomes. 2020;18(1):1–26. https://doi.org/10.1186/s12955-020-01511-z
Google Scholar6. Powell, PA, Carlton, J. “Social interaction (…) without that then I would probably be miserable”: understanding quality of life in Duchenne muscular dystrophy.” Qua Life Res. 2019;28(suppl 1):S109. https://doi.org/10.1007/s11136-019-02257-y
Google Scholar7. Powell, PA, Carlton, J, Rowen, D, Chandler, F, Guglieri, M, Brazier, JE. Development of a new quality of life measure for Duchenne muscular dystrophy using mixed methods: the DMD-QoL. Neurology. 2021;96(19):e2438–50. https://doi.org/10.1212/WNL.0000000000011896
Google Scholar8. Rowen, D, Powell, P, Mukuria, C, Carlton, J, Norman, R, Brazier, J. Deriving a preference-based measure for people with Duchenne muscular dystrophy from the DMD-QoL. Value Health. 2021;24(10):1499–1510.. https://doi.org/10.1016/j.jval.2021.03.007
Google Scholar